Welcome to our dedicated page for Zealand Pharma A/S news (Ticker: ZEAL), a resource for investors and traders seeking the latest updates and insights on Zealand Pharma A/S stock.
News about Zealand Pharma A/S (Nasdaq: ZEAL) centers on its work as a biotechnology company focused on peptide-based medicines for obesity and metabolic health, as well as its collaborations, clinical data and capital markets activity. Company announcements and partner press releases highlight progress across clinical trials, strategic agreements and shareholder developments.
Readers following ZEAL news will find updates on clinical programs such as BI 456906, a dual glucagon/GLP‑1 receptor agonist co‑invented with Boehringer Ingelheim. Phase II trial results reported by Boehringer Ingelheim and Zealand Pharma showed dose‑dependent weight loss in people living with obesity or overweight and in people with type 2 diabetes, reflecting the company’s focus on metabolic pathways. News also covers scientific presentations at major meetings, where Zealand Pharma shares preclinical and clinical data on investigational peptide candidates including dapiglutide, ZP8396 and ZP6590 for potential obesity and metabolic indications.
Another recurring news theme is strategic collaboration. For example, Zealand Pharma and OTR Therapeutics announced a multi‑program strategic collaboration and license agreement to discover and develop novel therapeutics for multiple targets in metabolic diseases. Under this agreement, OTR Therapeutics leads research and preclinical development using its proprietary discovery platform, while Zealand Pharma is responsible for clinical development, regulatory submissions and global commercialization.
Investors can also track company announcements on directed share offerings, private placements, capital increases and major shareholder notifications, which explain how Zealand Pharma raises funds to support its pipeline and disclose changes in ownership stakes. For ongoing insight into ZEAL’s clinical progress, partnerships and corporate actions, this news feed aggregates relevant releases and partner communications in one place.
Zealand Pharma has increased its share capital by DKK 47,045 through the exercise of employee warrants, resulting in 47,045 new shares being issued. The exercise prices varied, with DKK 135.30 for 1,934 shares, DKK 100.80 for 5,111 shares, and DKK 90.00 for 40,000 shares, totaling proceeds of DKK 4,376,859. Following this capital increase, Zealand Pharma’s share capital now stands at DKK 43,628,742. These new shares will be listed on Nasdaq Copenhagen, and each new share carries voting rights and the right to dividends.
Zealand Pharma announces its participation in the Jefferies London Healthcare Conference scheduled for November 18, 2021. Members of the senior management team will present at 3:00 a.m. EST (8:00 a.m. GMT). A pre-recorded webcast will be available on the company's website at the time of the presentation. Zealand Pharma specializes in developing peptide-based medicines, with more than 10 drug candidates in clinical development, two already on the market, and three in late-stage development, alongside partnerships with Boehringer Ingelheim and AstraZeneca.
Zealand Pharma A/S (Nasdaq: ZEAL) announced its financial results for the first nine months of 2021, reporting revenues of DKK 238.6 million (USD 37.1 million), down from DKK 290 million (USD 45.6 million) in 2020. Net operating expenses increased to DKK 906.2 million (USD 141.1 million), resulting in a net operating loss of DKK 762.6 million (USD 118.8 million). Cash and equivalents fell to DKK 1,049 million (USD 163.3 million). Zealand Pharma lowered its 2021 revenue guidance due to lower-than-expected sales of its product Zegalogue, projecting net product revenue of DKK 190 million +/- 10%.
Zealand Pharma has announced a collaboration with DEKA Research to develop a continuous infusion pump for dasiglucagon, targeting congenital hyperinsulinism (CHI). Zealand gains a worldwide, exclusive license for the pump, while DEKA will handle its development and manufacturing. Zealand is responsible for the clinical development and commercialization of the drug-device combination. This partnership aims to enhance treatment options for CHI, a rare pediatric condition.
Zealand Pharma has announced the dosing of the first subject in a Phase 1 clinical trial of ZP8396, an amylin analogue aimed at treating obesity. This single ascending dose trial will assess safety, tolerability, and pharmacokinetics in healthy volunteers. Preclinical data indicates that ZP8396 exhibits strong anti-obesity effects both as a standalone treatment and in combination with GLP-1 analogues. The trial is a significant milestone for Zealand Pharma as it pursues innovative peptide-based medicines for obesity and metabolic conditions.
Zealand Pharma announces a conference call on November 11, 2021, at 4 PM CET (10 AM ET) to discuss its third quarter results. The call will feature key executives including CEO Emmanuel Dulac and CFO Matt Dallas, followed by a Q&A session. The event will be conducted in English, with dial-in numbers available for several countries. Interested participants can access a live audio webcast and slides through Zealand’s investor website. Zealand Pharma focuses on innovative peptide-based medicines and has marketed products like V-Go and Zegalogue.
Zealand Pharma presents promising preclinical data for its amylin analogue ZP8396 and clinical data for BI 456906, a glucagon-GLP1 dual-agonist, at the Obesity Society Annual Meeting. The preclinical results indicate up to 20% weight loss in in vivo models when ZP8396 is combined with semaglutide. Meanwhile, BI 456906 demonstrated clinically relevant body weight reductions of up to 13.7% over 16 weeks in a Phase 1 trial. Both compounds showcase Zealand's innovative pipeline aimed at treating obesity, with further studies planned.
Zealand Pharma (NASDAQ: ZEAL) announced an update regarding its share capital as of September 30, 2021. The company confirmed a total of 43,581,697 shares with a corresponding nominal value of DKK 1 per share, which also represents the total number of voting rights. This announcement follows a previous update on September 10, 2021, regarding the exercise of employee warrants that contributed to the change in share capital.
Zealand Pharma A/S (Nasdaq: ZEAL) announced transactions involving its shares conducted by managerial personnel and their associates. This disclosure is a standard regulatory requirement aimed at maintaining transparency in trading activities. Zealand, focused on peptide-based medicines, has two marketed products: V-Go® for diabetes management and Zegalogue® for severe hypoglycemia. The company has advanced several drug candidates into clinical development, showcasing its commitment to innovation in biotechnology.
Zealand Pharma (Nasdaq: ZEAL) announced a share capital increase of DKK 30,748, equating to 30,748 new shares, due to the exercise of employee warrants on September 10, 2021. The exercise prices varied, with DKK 135.30 for 8,089 shares, DKK 100.80 for 14,000 shares, and DKK 138.60 for 8,659 shares, leading to total proceeds of DKK 3,705,779.10. The new shares will be listed on Nasdaq Copenhagen, increasing the total share capital to DKK 43,581,697.